Decreased Tenofovir Diphosphate Concentrations in a Transgender Female Cohort: Implications for Human Immunodeficiency Virus Preexposure Prophylaxis. (9th April 2019)

• Record Type: Journal Article
• Authors: Cottrell, Mackenzie L; Prince, Heather M A; Schauer, Amanda P; Sykes, Craig; Maffuid, Kaitlyn; Poliseno, Amanda; Chun, Tae-Wook; Huiting, Erin; Stanczyk, Frank Z; Peery, Anne F; Dellon, Evan S; Adams, Jessica L; Gay, Cindy; Kashuba, Angela D M
• Is Part Of: Clinical infectious diseases. Volume 69:Number 12(2019)
• Page Start: 2201
• Page End: 2204
• Publication Date: 2019-04-09
• Subjects: transgender -- preexposure prophylaxis -- lower gastrointestinal tract -- HIV -- feminizing hormone therapy; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciz290
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Feminizing hormone therapy (FHT) may interact with human immunodeficiency virus preexposure prophylaxis (PrEP). We found that transgender women who took FHT exhibited a 7-fold lower rectal tissue ratio of PrEP's active metabolites vs competing deoxynucleotides compared to cisgender women and men ( P = .03) that inversely correlated with estradiol (ρ = –0.79; P < .05). Thus, FHT may negatively impact PrEP efficacy. Clinical Trials Registration . NCT02983110.